Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

BRIDGE-HIV Bridging Reservoir Science, Integrated Drug Discovery, Big Data Analytics, Artificial Intelligence and Epidemiology

Coordinator
Erasmus Universitair Medisch Centrum Rotterdam, Netherlands
Runs
1 October 2026 to 30 September 2030
Status
Running
EU funding
€1.7m
Total cost
—
Partners
11 organisations in 7 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101300096

What the project is doing

In the project's own words, from its summary on CORDIS.

This mobility program will advance research and innovation (R&I) in Human immunodeficiency virus (HIV) persistence by partnering European and African institutions to co-develop robust, reproducible pipelines spanning ex vivo and reservoir assays, organoid based pharmacology, multi-omics integration, geospatial science, and artificial intelligence (AI) driven analytics. European R&I infrastructure capacity and established clinical cohorts, accredited laboratories, and proven assays already operationalized in African partner institutions, the project will generate calibrated feature sets to define reproducible immunological and molecular endotypes that inform long-acting antiretroviral therapy (LA-ART) and “block-and-lock” therapeutic strategies while creating opportunities for interdisciplinary, international and intersectoral transfer of knowledge.

This will result to improved understanding of HIV reservoirs and positively impact capacity of EU researchers facilitated by bidirectional staff-exchanges across sectors and regions, pairing hands-on laboratory and clinical method transfer with data engineering, machine learning operations, and spatial epidemiology skills. European Countries will benefit through strengthened HIV research knowledge in implementation science, diversified evidence bases that improve the validity and generalizability of biomarkers and models across genotypes and comorbidity profiles, strengthened research infrastructures through shared protocols and reusable open tools.

By pairing African established cohorts and proven assays with European strengths in infrastructure and capacity in HIV, immunology and organoid R&I, the consortium delivers durable scientific value for Europe and accelerates fair, scalable translation from discovery to policy and practice.

Topics

Who is involved

OrganisationCityCountryRole
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsCoordinator
Erevnitiko Kentro Vioiatrikon Epistimon Alexandros FlemingkVari-AthensGreeceParticipant
Genolytica E.e.KallitheaGreeceParticipant
International Centre for Genetic Engineering and BiotechnologyTriesteItalyParticipant
Hub Organoids BVUtrechtNetherlandsParticipant
Makerere UniversityKampalaUGAssociatedpartner
University College LondonLondonUnited KingdomParticipant
Africa Health Research Institute (ahri)DurbanSouth AfricaAssociatedpartner
University of Kwazulu-NatalWestvilleSouth AfricaAssociatedpartner
Centre for Infectious Disease Research in Zambia LimitedLusakaZMAssociatedpartner
Verdaia Consulting LtdLusakaZMAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI